Clinical Efficacy and Safety of Aidi Injection Plus Docetaxel-Based Chemotherapy in Advanced Nonsmall Cell Lung Cancer: A Meta-Analysis of 36 Randomized Controlled Trials

Table 2

Meta-analysis results of acute/chronic toxicity (Figures S1-7).

Outcomes	Studies	Experimental group (Evens/tatol)	Control groups (Evens/tatol)	SM	RR (95 CI)	I^2	P
Neutropenia (Figure S1)	26	452/1007	627/999	REM	0.70 [0.61, 0.79]	73%	P < 0.00001
Thrombocytopenia (Figure S2)	17	153/715	235/700	FEM	0.63 [0.53, 0.75]	0%	P < 0.00001
Anemia (Figure S3)	9	85/353	135/343	FEM	0.60 [0.48, 0.75]	0%	P < 0.00001
Gastrointestinal toxicity (Figure S4)	26	504/1060	634/1053	REM	0.76 [0.65, 0.89]	88%	P = 0.0006
Liver dysfunction (Figure S5)	7	37/308	52/293	FEM	0.69 [0.47, 1.01]	0%	P = 0.05
Renal dysfunction (Figure S5)	5	15/181	26/173	FEM	0.56 [0.31, 1.00]	0%	P = 0.05
Hepatorenal dysfunctions (Figure S5)	5	23/147	40/146	FEM	0.56 [0.36, 0.88]	0%	P = 0.01
Neurotoxicity (Figure S6)	5	42/192	66/184	REM	0.65 [0.35, 1.18]	56%	P = 0.16
Alopecia (Figure S7)	3	16/98	27/92	FEM	0.58 [0.36, 0.93]	0%	P = 0.02
Rash (Figure S7)	2	12/88	15/83	FEM	0.75 [0.38, 1.49]	2%	P = 0.42
Phlebitis (Figure S7)	3	25/113	25/113	FEM	1.00 [0.63, 1.59]	0%	P = 1.00
Oral mucositis (Figure S7)	3	18/110	28/110	FEM	0.64 [0.38, 1.09]	0%	P = 0.10

Note: SM: statistical method; REM: random-effects model; FEM: fixed-effects model; RR: risk ratios.